2017 · PRESSE MEDICALE

Adverse effects of immune checkpoint inhibitors used to treat melanoma and other cancer

Jacquin-Porretaz, Claire, Nardin, Charlee, Puzenat, Eve, Roche-Kubler, Blandine, Aubin, Francois, Schillo, Franck, Meillet, Lucie, Borot, Sophie, Vuitton, Lucine, Koch, Stephane, Westeel, Virginie, Jacoulet, Pascale, Cervoni, Jean Paul, Di Martino, Vincent, Chauchet, Adrien, Wendling, Daniel, Badoz, Marc, Ducloux, Didier, Tatu, Laurent, Delbosc, Bernard, CSESIAC

Journal: PRESSE MEDICALE
Année: 2017
Volume: 46
Numéro: 9
Pages: 808-817
Mois: SEP
DOI: 10.1016/j.lpm.2017.05.032

Abstract

Monoclonal antibodies targeted against the immune checkpoint molecules CTLA-4 and PD-1 have recently obtained approval for the treatment of metastatic melanoma and advanced/refractory non small-cell lung cancers and metastatic renal cancer. Besides their efficacy profile, these immune targeted agents also generate immune-related adverse events that may be life threatening if not anticipated and managed appropriately. This new family of dysimmune toxicities remains largely unknown to the broad oncology community. We propose here some practical guidelines for the oncologist to help in the clinical care of patients under immune checkpoint molecules.

Lire l'article complet